October 20, 2021
Vimpat® (lacosamide – UCB, Inc.) has been approved to treat partial-onset seizures in patients who are at least one month old. This indication was previously FDA approved only for individuals four years of age and older.
- The expanded indication applies to the drug’s oral film-coated tablet, intravenous injection, and oral solution dosage The recommended dosing for partial onset seizures is based on factors that may include the patient’s age, response to treatment, and body weight.
- First FDA approved in 2008, Vimpat is also indicated to treat primary generalized tonic-clonic seizures in patients who are at least four years old.